Understand the mechanisms being studied, the evidence available, and the questions that remain open.
MetabolicAOD-9604 is a modified fragment related to the C-terminal region of human growth hormone. It was investigated for metabolic and weight-related effects. Describing it as a fragment of a familiar hormone does not establish that it shares every action, benefit, or safety property of that hormone.
MetabolicCagrilintide is a long-acting amylin analog studied for weight management, including in combination with semaglutide. A combination name describes a development program, not proof that an independently purchased mixture has the same identity, quality, or clinical evidence.
MetabolicLiraglutide is a prescription GLP-1 receptor agonist used in distinct products for diabetes and weight management. Victoza and Saxenda contain the same active ingredient but have different labeled purposes and treatment instructions. Their use should be discussed in relation to the patient’s diagnosis rather than grouped into a generic peptide protocol.
MetabolicMazdutide is a dual GLP-1 and glucagon receptor agonist studied for obesity and metabolic disease. It belongs to a different receptor combination from tirzepatide. Regulatory developments outside the United States should be described separately from United States approval and availability.
MetabolicMOTS-c is a short peptide associated with mitochondrial genetic signaling. It is studied for links among cellular stress, metabolism, and communication between mitochondria and the rest of the cell. An endogenous peptide being measurable in people does not establish that supplementing it is beneficial.
MetabolicRetatrutide is an investigational peptide designed to activate GIP, GLP-1, and glucagon receptors. The combination has generated interest in obesity and metabolic research. It remains important to distinguish an investigational study drug from a product advertised online under the same name.
MetabolicSemaglutide is a GLP-1 receptor agonist available in multiple prescription products. Ozempic, Wegovy, and Rybelsus are familiar brand names, but they should not be treated as interchangeable instructions. Different formulations and strengths have different labels, approved uses, administration requirements, and patient populations.
MetabolicSLU-PP-332 is an experimental small molecule, not a peptide. It is included here because it frequently appears in peptide catalogs and exercise-mimetic discussions. Its research history is primarily preclinical, so a mouse endurance finding should not be presented as a human fitness treatment.
MetabolicSurvodutide is an investigational dual glucagon and GLP-1 receptor agonist. Research includes obesity and metabolic liver-disease questions. The compound should be distinguished from approved incretin products and from other dual agonists with different receptor targets.
MetabolicTesofensine is an investigational monoamine reuptake inhibitor, not a peptide. It is discussed in some peptide-oriented weight-management catalogs, which can obscure its different chemistry and pharmacology. It should not be grouped with GLP-1 medicines as though they were the same class.
MetabolicTirzepatide is a prescription peptide that activates two incretin receptors, GIP and GLP-1. In the United States, approved products include Mounjaro and Zepbound. Those brands have different labeled uses, so the ingredient name alone does not identify the indication, eligibility criteria, presentation, or insurance coverage.
| Compound | Research topic | Overview | Guide |
|---|---|---|---|
| AOD-9604 | Metabolic | AOD-9604 is a modified fragment related to the C-terminal region of human growth hormone. It was investigated for metabolic and weight-related effects. Describing it as a fragment of a familiar hormone does not establish that it shares every action, benefit, or safety property of that hormone. | Read ↗ |
| Cagrilintide | Metabolic | Cagrilintide is a long-acting amylin analog studied for weight management, including in combination with semaglutide. A combination name describes a development program, not proof that an independently purchased mixture has the same identity, quality, or clinical evidence. | Read ↗ |
| Liraglutide | Metabolic | Liraglutide is a prescription GLP-1 receptor agonist used in distinct products for diabetes and weight management. Victoza and Saxenda contain the same active ingredient but have different labeled purposes and treatment instructions. Their use should be discussed in relation to the patient’s diagnosis rather than grouped into a generic peptide protocol. | Read ↗ |
| Mazdutide | Metabolic | Mazdutide is a dual GLP-1 and glucagon receptor agonist studied for obesity and metabolic disease. It belongs to a different receptor combination from tirzepatide. Regulatory developments outside the United States should be described separately from United States approval and availability. | Read ↗ |
| MOTS-c | Metabolic | MOTS-c is a short peptide associated with mitochondrial genetic signaling. It is studied for links among cellular stress, metabolism, and communication between mitochondria and the rest of the cell. An endogenous peptide being measurable in people does not establish that supplementing it is beneficial. | Read ↗ |
| Retatrutide | Metabolic | Retatrutide is an investigational peptide designed to activate GIP, GLP-1, and glucagon receptors. The combination has generated interest in obesity and metabolic research. It remains important to distinguish an investigational study drug from a product advertised online under the same name. | Read ↗ |
| Semaglutide | Metabolic | Semaglutide is a GLP-1 receptor agonist available in multiple prescription products. Ozempic, Wegovy, and Rybelsus are familiar brand names, but they should not be treated as interchangeable instructions. Different formulations and strengths have different labels, approved uses, administration requirements, and patient populations. | Read ↗ |
| SLU-PP-332 | Metabolic | SLU-PP-332 is an experimental small molecule, not a peptide. It is included here because it frequently appears in peptide catalogs and exercise-mimetic discussions. Its research history is primarily preclinical, so a mouse endurance finding should not be presented as a human fitness treatment. | Read ↗ |
| Survodutide | Metabolic | Survodutide is an investigational dual glucagon and GLP-1 receptor agonist. Research includes obesity and metabolic liver-disease questions. The compound should be distinguished from approved incretin products and from other dual agonists with different receptor targets. | Read ↗ |
| Tesofensine | Metabolic | Tesofensine is an investigational monoamine reuptake inhibitor, not a peptide. It is discussed in some peptide-oriented weight-management catalogs, which can obscure its different chemistry and pharmacology. It should not be grouped with GLP-1 medicines as though they were the same class. | Read ↗ |
| Tirzepatide | Metabolic | Tirzepatide is a prescription peptide that activates two incretin receptors, GIP and GLP-1. In the United States, approved products include Mounjaro and Zepbound. Those brands have different labeled uses, so the ingredient name alone does not identify the indication, eligibility criteria, presentation, or insurance coverage. | Read ↗ |